Tower Research Capital (TRC)’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-2,426
| Closed | -$5K | – | 6968 |
|
|
2022
Q2 | $5K | Buy |
+2,426
| New | +$4.84K | ﹤0.01% | 5157 |
|
|
2022
Q1 | – | Sell |
-4,000
| Closed | -$9K | – | 7072 |
|
|
2021
Q4 | $9K | Sell |
4,000
-11,093
| -73% | -$30K | ﹤0.01% | 4767 |
|
|
2021
Q3 | $50K | Buy |
+15,093
| New | +$40.9K | ﹤0.01% | 2975 |
|
|
2021
Q2 | – | Sell |
-13,918
| Closed | -$30K | – | 6155 |
|
|
2021
Q1 | $30K | Buy |
+13,918
| New | +$39.6K | ﹤0.01% | 3578 |
|
|
2020
Q4 | – | Sell |
-13,120
| Closed | -$27K | – | 5531 |
|
|
2020
Q3 | $27K | Buy |
13,120
+4,372
| +50% | +$12.5K | ﹤0.01% | 3769 |
|
|
2020
Q2 | $26K | Buy |
+8,748
| New | +$23.9K | ﹤0.01% | 3552 |
|
|
2020
Q1 | – | Sell |
-140
| Closed | -$1K | – | 4247 |
|
|
2019
Q4 | $1K | Sell |
140
-45
| -24% | -$244 | ﹤0.01% | 3379 |
|
|
2019
Q3 | $1K | Sell |
185
-1,272
| -87% | -$8.53K | ﹤0.01% | 3979 |
|
|
2019
Q2 | $9K | Buy |
1,457
+379
| +35% | +$2.44K | ﹤0.01% | 2647 |
|
|
2019
Q1 | $7K | Sell |
1,078
-320
| -23% | -$1.92K | ﹤0.01% | 2908 |
|
|
2018
Q4 | $6K | Buy |
+1,398
| New | +$9.21K | ﹤0.01% | 2845 |
|
Tower Research Capital (TRC)'s ETTX Position: Q3 2022 in Review
Tower Research Capital (TRC) sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 2,426 shares — an estimated $5K sold.
Tower Research Capital (TRC) first reported a position in ETTX in Q4 2018 and held it in 11 quarters. The position peaked at $50K in Q3 2021. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.
- Tower Research Capital (TRC) reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,426 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $5K.
- Tower Research Capital (TRC) first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2018 and held it in 11 quarters.
- Tower Research Capital (TRC)'s Entasis Therapeutics Holdings Inc. position peaked at $50K in Q3 2021.
- 0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.